keyboard_arrow_right
Search keyboard_arrow_right
keyboard_arrow_left Hide
Day 3: Main Conference
search
Day 3: Main Conference
search
Showing 1 of 1 Streams
Morning Spotlight Presentation
07:30 - 08:00
NMR spectroscopy, just what you need to assure the quality of your TIDES
The wealth of structural information that accompanies NMR spectroscopy has made it instrumental for traditional small molecules medicinal and analytical chemistry support. Perhaps less well known is its ability to characterise TIDES efficiently and with such a level of detail (atomic resolution). This talk demonstrates its power with examples covering TIDES structure-based drug design,1,2 similarity assessment,3 characterisation,4 secondary and tertiary structure, quantification and phosphorothioate chirality.5,6
- Anna Codina, PhD - Director Pharmaceutical Business Unit, Bruker BioSpin
Showing 3 of 3 Streams
Oligonucleotide Track
Peptide Track
Macromolecular Delivery and Conjugation Strategies
08:00 - 08:05
Chairperson’s Remarks
- Mike Webb, Ph.D. - Founder and CEO, Mike Webb Pharma
08:05 - 08:30
An Update on the Mission, Goals and Progress of the UK Nucleic Acid Therapy Accelerator
- Nick Lench, Ph.D. - Executive Director, The MRC Nucleic Acid Therapy Accelerator
08:30 - 08:55
Amidite Control Strategies in a Commercial Environment
- Jonas Watzel, PhD - Head of Quality Control Lab, BioSpring GmbH
08:55 - 09:20
An Alternative Approach to Make Amidite Blocks and Full-Length Oligonucleotide Products via Newly Developed Liquid Phase Oligonucleotide Synthesis
- Jun Young Choi - Head of R&D, ST Pharm
09:20 - 09:45
Application of Bioburden Control in Oligonucleotide Manufacturing
- Achim Geiser, Ph.D. - Synthetic Molecules Technical Development, External Technical Oversight Manager, F Hoffmann-La Roche Ltd
08:00 - 08:05
Chairperson's Remarks
- Christian Becker - Professor and Head of the Institute of Biological, University of Vienna
08:05 - 08:30
mRNA Display, Macrocyclic Peptides and Selective Chemical Modifications
- Seino Jongkees, Ph.D. - Associate Professor, VU Amsterdam
08:30 - 08:55
Taking Inspiration from Nature to Design Novel Chemistries for Protein Chemical Synthesis
- Oleg Melnyk, Ph.D. - Research Director, CNRS
08:55 - 09:20
Design of Peptide Based GLP-1 Agonists with Improved Oral Bioavailability
- Janos Kodra, PhD - Principal Scientist, Research Chemistry, Novo Nordisk A/S
09:20 - 09:45
Strategies for Half-Life Extension of Peptide Pharmaceuticals
- Soren Ostergaard, Ph.D. - Principal Scientist, Research Chemistry 3, Novo Nordisk A/S
08:00 - 08:05
Chairperson's Remarks
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals
08:05 - 08:30
Therapeutic RNA Delivery into the Brain Using Protein-based Nanocapsules
- Ekkehard Leberer, PhD - Scientific Advisor, NEUWAY Pharma & Life Sciences Consultant, ELBIOCON
08:30 - 08:55
Development of Targeted Oligonucleotide Therapy for Respiratory Diseases
- Thomas Frischmuth - Managing Director, baseclick GmbH
08:55 - 09:20
Use of a Lipophilic-conjugation to Deliver Antimir-23b into Skeletal Muscle and Nervous System for the Treatment of DM1
- Beatriz Llamusi, PhD - Chief Executive Officer & Co Founder, Arthex Biotech
09:20 - 09:45
Knocking Down Barriers: Advances in Synthesis and Delivery of Morpholino Antisense In vitro and In vivo
- Surajit Sinha - ., Indian Association for the Cultiva of SC
09:45 - 10:30
Networking Refreshment Break in Poster and Exhibit Hall
Showing 3 of 3 Streams
Oligonucleotide Track
Peptide Track
Macromolecular Delivery and Conjugation Strategies
10:30 - 11:00
How to Manage an ASO Program with the DP Delivered by Intrathecal Injection? - A CMC Perspective
- Hagen Cramer, PhD - Chief Production Officer, QurAlis
11:00 - 11:30
EMA Draft Concept Paper on the Establishment of a Guideline on the Development and Manufacture of Synthetic Oligonucleotides
- René Thürmer, PhD - Deputy Head, BfArM Federal Institute for Drugs & Medical Devices
10:30 - 11:00
Synthetic Peptides – Scientific Considerations on Pharmaceutical Quality Aspects: EMA Experience and Future Outlooks
- Hilde Bastaerts, PharmD - Pharmaceutical Quality Specialist, European Medicines Agency
11:00 - 11:30
Meeting the Clinical Demands of Neoantigen Manufacturing to Support Immunotherapies
- Daniel DeOliveira, PhD - Principal Consultant, Life Sciences Project Management
10:30 - 11:00
Tailoring Lipid-based Nanocarriers for Site-specific RNA Delivery
- Maria Alonso, Ph.D. - Full Professor, CIMUS Research Institute
11:00 - 11:30
Splice Modulating RNA Targeting Therapies for Brain Disorders: From Treating Many to Treating One
- Willeke van Roon-Mom, Ph.D. - Professor Translational Studies of Neurodegenerative Disorders, Leiden University Medical Center
Showing 3 of 3 Streams
Spotlight Presentation 1
Spotlight Presentation 2
Spotlight Presentation 3
11:35 - 12:05
The Process Development for Blockmer™ Synthesis in Liquid-phase
- Ichiro Mori, PhD - Director of Quality Assurance/CQO, NATiAS Inc.
11:35 - 12:05
Going Green: Sustainability Solutions in Oligonucleotide Manufacturing
- Jessica Beese, PhD - Project Lead GMP and Large Scale Production, BioSpring GmbH
11:35 - 12:05
Characterization and Quantification of Oligonucleotide and RNA Impurities by CE and LC-MS
- Stephen Lock, PhD - Senior Market Development Manager, SCIEX
12:05 - 13:25
Networking Luncheon in Poster and Exhibit Hall
Showing 3 of 3 Streams
Spotlight Presentation 1
Spotlight Presentation 2
Spotlight Presentation 3
13:25 - 13:55
Revolutionizing Nucleic Acid Synthesis with Engineered Enzymes
- David Entwistle, Ph.D. - Head of Process Chemistry, Codexis
13:25 - 13:55
Developing a Composite Purity Analysis of Single Guide RNA
- John Walker II, PhD - Vice President of Chemical Sciences, Synthego
13:25 - 13:55
Creating a Comprehensive Toolbox for Oligonucleotide Drug Discovery and Development
- Dave Madge, PhD - Vice President, Research Services Division, WuXi AppTec
Showing 3 of 3 Streams
Oligonucleotide Track
Peptide Track
Macromolecular Delivery and Conjugation Strategies
13:55 - 14:00
Chairman's Remarks
- Christian Wetter, Ph.D. - Portfolio Leader, Pharma Technical Regulatory, Roche
14:00 - 14:30
Microbial Control Strategies for Oligonucleotide DS Manufacturing
- Sandra Tremmel, Ph.D. - Microbiology Engineer, QC Technical Innovation, F. Hoffmann-La Roche Ltd.
14:30 - 15:00
Regulatory Strategies for Use of Platform Data in Oligonucleotide Development
- Chris Chorley - Associate Director, Global Regulatory CMC, ASO Early Development Lead, Biogen
15:00 - 15:30
Nitrosamine and Mutagenic Impurity Risk Assessments in Oligonucleotides
- Gair Ford, Ph.D. - Regulatory CMC Director, Astrazeneca
13:55 - 14:00
Chairman's Remarks
- Georgios Georgopoulos - Business Development Manager, Bachem AG
14:00 - 14:30
Current Chemical Strategies in Extending Half-Lives of Therapeutic Peptides
- El Djouhar Rekai, PhD - Head of Peptide Process Development and Manufacturing LCM, PolyPeptide Group
14:30 - 15:00
Challenges and Solutions in Peptide Reference Standards Characterization, Establishment, Purity Assignment and Usage During Clinical Development Programmes
- Osama Chahrour, Ph.D. - Senior New Modalities Leader, AstraZeneca
15:00 - 15:30
Benchmarking Synthetic Peptide Sustainability: On Behalf of Peptides sub-team, ACS Green Chemistry Institute Pharmaceutical Roundtable
- Martin Kenworthy, Ph.D. - Associate Principal Scientist, AstraZeneca
13:55 - 14:00
Chairman's Remarks
- Yogesh Sanghvi, PhD - President, Rasayan Inc.
14:00 - 14:30
Novel Approaches for Synthesis of Oligonucleotide Conjugates
- Ramon Eritja Casadella, Ph.D. - Research Professor, IQAC-CSIC
14:30 - 15:00
Process Development Challenges for non-Hepatic Targeted siRNA Therapeutics
- Fred Fleitz - Group Vice President, CMC, Arrowhead Pharmaceuticals
15:00 - 15:30
CMC Challenges in Conjugation Chemistry
- Lubomir Nechev, PhD - Vice President, Process and Analytical Sciences, Alnylam Pharmaceuticals, Inc.
15:30 - 16:00
Close of Peptide Stream and Networking Refreshment Break in Poster and Exhibit Hall
Showing 2 of 2 Streams
Oligonucleotide Track
Macromolecular Delivery & Conjugation Strategies
16:00 - 16:30
Regulatory CMC Interactions and Intelligence for Oligonucleotide Programs
- Tracey Burr, Ph.D. - Executive Director, CMC Regulatory Affairs, Ionis Pharmaceuticals
16:30 - 17:00
Terminal Sterilisation of Oligonucleotides
- Nadim Akhtar, PhD - Principal Scientist, AstraZeneca
17:00 - 17:30
Lessons Learned on the Evaluation of Terminal Sterilization for Oligonucleotide Drug Products
- Aude Figuccia, Ph.D. - Regulatory Affairs CMC Senior Manager, Novartis
16:00 - 16:30
The Power of Delivery when Oligonucleotides and Peptides Come Together: The Peptide Perspective
- Katie Gaynor, Ph.D. - Principal Scientist, Bicycle Therapeutics
16:30 - 17:00
The Power of Delivery when Oligonucleotides and Peptides Come Together: The Oligonucleotide Perspective
- Michele Carrer, PhD - Director, Department of Neurology, Ionis Pharmaceuticals
17:00 - 17:30
RNA to Deliver RNA: Programmable Delivery Systems for Targeted Non- hepatic Delivery
- Anna Perdrix Rosell - Founder and Co-CEO, Sixfold Bioscience
17:30 - 18:30
Close of Conference
Get the Latest Event Updates
Sign up to get the latest event updates and information.